SOX9 also drives prostate cancer development through WNT pathway activation; treatment of SOX9-expressing prostate cancers with a WNT synthesis inhibitor reduces WNT pathway signaling and tumor growth in murine xenograft models [304]. This evidence concerns the gene SOX9 and prostate carcinoma.